ESMO 2014

Oncology Meeting Resources

26 Sep - 30 Sep 2014, Madrid, Spain

ESMO 2014 Congress

The theme for ESMO 2014 was ‘Precision Medicine in Cancer Care.’ Whether you are a medical or surgical oncologist or a radiation oncologist, immunologist or pathologist, practising precision medicine means we are all working towards a common goal – improved patient outcomes. For your convenience and due to the large quantity of information coming from the ESMO 2014 congress, we have split the presentations up by main congress topic to allow you to find the information you need more easily.

Here, you will find the abstracts, posters, PDF presentation and webcasts from ESMO 2014 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Drug Index of ESMO 2014 Abstracts

Special Sessions and Tracks

Useful links





Format available

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Invited-discussant-abstract-LBA30

Date: 27 Sep 2014
Presenter: Sandrine Faivre
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...-differentiated-cancer-of-the-thyroid-SELECT

AimLenvatinib (LEN)—an oral multikinase inhibitor of VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT—significantly prolonged progression-free survival (PFS) vs placebo (PBO) in patients (pts) with...

Date: 27 Sep 2014
Presenter: Makoto Tahara
Resources: Abstract, Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...and-progressive-medullary-thyroid-cancer-MTC

AimVandetanib has demonstrated efficacy in advanced MTC in a large phase III trial (NCT00410761). However, little evidence is available on safety and efficacy of vandetanib in daily-practice patients.

Date: 27 Sep 2014
Presenter: Enrique Grande
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer

http://oncologypro.esmo.org/Meeting-Resourc...idectomy-for-papillary-thyroid-carcinoma-PTC

AimThe recurrence of PTC is frequent in regional lymph node. Most of them need reoperation. The purpose of this study was to evaluate the serum thyroglobulin(Tg) levels before and after the second...

Date: 27 Sep 2014
Presenter: DongHui Cho
Resources: Abstract
Topics: Thyroid Cancer, Surgery and/or Radiotherapy of Cancer

http://oncologypro.esmo.org/Meeting-Resourc...ncer-differentiated-medullary-and-anaplastic

AimLEN is an oral tyrosine kinase inhibitor targeting VEGFR1-3, FGFR1-4, RET, KIT and PDGFRß, and showed a prominent improvement in progression free survival (PFS) in pts with radioiodine-refractory...

Date: 28 Sep 2014
Presenter: Shunji Takahashi
Resources: Abstract
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...d-discussant-abstracts-993Pd-994PD-and-995PD

Date: 28 Sep 2014
Presenter: Lisa Licitra
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Head and Neck Cancers

http://oncologypro.esmo.org/Meeting-Resources/ESMO-2014/Practical-management-of-TKI

Date: 28 Sep 2014
Presenter: Jaume Capdevila
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer

http://oncologypro.esmo.org/Meeting-Resourc...2014/Sub-classification-and-treatment-of-MTC

Date: 28 Sep 2014
Presenter: Sophie Leboulleux
Resources: Presentation, Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Pathology/Molecular Biology

http://oncologypro.esmo.org/Meeting-Resourc...tory-DTC-Patient-Optimizing-Clinical-Benefit

Date: 28 Sep 2014
Presenter: Martin J. Schlumberger
Resources: Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Translational Research

http://oncologypro.esmo.org/Meeting-Resourc...-With-Systemic-Therapy-in-RAI-Refractory-DTC

Date: 28 Sep 2014
Presenter: Marcia Brose
Resources: Webcast
Topics: Anti-Cancer Agents & Biologic Therapy, Thyroid Cancer, Translational Research